99 related articles for article (PubMed ID: 24370033)
21. [Salvage therapy with proteasome inhibitor bortezomib for relapsed and refractory multiple myeloma].
Huang WR; Li R; Jing Y; Zhang YZ; Wu XX; Gao CJ; Bo J; Yu L; Wang QS; Da WM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Dec; 14(6):1146-50. PubMed ID: 17204182
[TBL] [Abstract][Full Text] [Related]
22. Sequential treatment with bortezomib plus dexamethasone followed by autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
Zheng D; Li J; Huang BH; Liu JR; Zou WY; Su C
Chin Med J (Engl); 2012 Dec; 125(24):4454-9. PubMed ID: 23253719
[TBL] [Abstract][Full Text] [Related]
23. [Outcome of bortezomib plus chemotherapy with or without stem cell transplantation for treatment of multiple myeloma].
Wang YF; Deng SH; Wu T; Xu Y; Zou DH; Wang Y; Zhao YZ; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2008 Jun; 29(6):397-400. PubMed ID: 19031743
[TBL] [Abstract][Full Text] [Related]
24. A pilot study of bortezomib in Korean patients with relapsed or refractory myeloma.
Lee KW; Yun T; Song EK; Na II; Shin H; Bang SM; Lee JH; Lee ST; Kim JH; Yoon SS; Lee JS; Park S; Kim BK; Kim NK
J Korean Med Sci; 2005 Aug; 20(4):598-62. PubMed ID: 16100450
[TBL] [Abstract][Full Text] [Related]
25. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
[TBL] [Abstract][Full Text] [Related]
26. [Observational retrospective study to evaluate the effectiveness and safety of treatment schemes with bortezomib for multiple myeloma in our hospital].
Titos-Arcos JC; León-Villar J; de Arriba de la Fuente F; Moreno Belmonte MJ; Iranzo Fernández MD
Farm Hosp; 2012; 36(4):275-81. PubMed ID: 22115856
[TBL] [Abstract][Full Text] [Related]
27. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma.
Jagannath S; Durie BG; Wolf J; Camacho E; Irwin D; Lutzky J; McKinley M; Gabayan E; Mazumder A; Schenkein D; Crowley J
Br J Haematol; 2005 Jun; 129(6):776-83. PubMed ID: 15953004
[TBL] [Abstract][Full Text] [Related]
28. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.
Jagannath S; Barlogie B; Berenson J; Siegel D; Irwin D; Richardson PG; Niesvizky R; Alexanian R; Limentani SA; Alsina M; Adams J; Kauffman M; Esseltine DL; Schenkein DP; Anderson KC
Br J Haematol; 2004 Oct; 127(2):165-72. PubMed ID: 15461622
[TBL] [Abstract][Full Text] [Related]
29. Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma.
Ning YM; He K; Dagher R; Sridhara R; Farrell AT; Justice R; Pazdur R
Oncology (Williston Park); 2007 Nov; 21(12):1503-8; discussion 1511, 1513, 1516 passim. PubMed ID: 18077994
[TBL] [Abstract][Full Text] [Related]
30. Inhibitory effects of bortezomib on platelet aggregation in patients with multiple myeloma.
Rupa-Matysek J; Gil L; Wojtasińska E; Nowicki A; Dytfeld D; Kaźmierczak M; Komarnicki M
Thromb Res; 2014 Aug; 134(2):404-11. PubMed ID: 24931724
[TBL] [Abstract][Full Text] [Related]
31. The safety and efficacy of bortezomib in relapsed multiple myeloma.
Jagannath S
Clin Adv Hematol Oncol; 2006 May; 4(5):2-3; discussion 8; suppl 13. PubMed ID: 16830423
[No Abstract] [Full Text] [Related]
32. [Treatment with a proteasome inhibitor, bortezomib, for thalidomide-resistant multiple myeloma].
Takatoku M; Noborio-Hatano K; Takahashi S; Kikuchi S; Mori M; Muroi K; Komatsu N; Ozawa K
Rinsho Ketsueki; 2004 Feb; 45(2):144-8. PubMed ID: 15045823
[TBL] [Abstract][Full Text] [Related]
33. Bortezomib for previously untreated multiple myeloma.
de la Rubia J; Roig M
Expert Rev Hematol; 2011 Aug; 4(4):381-98. PubMed ID: 21801129
[TBL] [Abstract][Full Text] [Related]
34. A phase 2 study of bortezomib in relapsed, refractory myeloma.
Richardson PG; Barlogie B; Berenson J; Singhal S; Jagannath S; Irwin D; Rajkumar SV; Srkalovic G; Alsina M; Alexanian R; Siegel D; Orlowski RZ; Kuter D; Limentani SA; Lee S; Hideshima T; Esseltine DL; Kauffman M; Adams J; Schenkein DP; Anderson KC
N Engl J Med; 2003 Jun; 348(26):2609-17. PubMed ID: 12826635
[TBL] [Abstract][Full Text] [Related]
35. [Efficacy of bortezomib combined dexamethasone in 24 patients with multiple myeloma].
Li J; Zhao Y; Luo SK; Huang BH; Ding Y; Tong XZ; Wang HH; Zheng D; Su C; Peng AH
Ai Zheng; 2008 Apr; 27(4):429-34. PubMed ID: 18423132
[TBL] [Abstract][Full Text] [Related]
36. Assessment of the Effect of Methotrexate Therapy on Bone Metabolism in Patients with Rheumatoid Arthritis.
Świerkot J; Gruszecka K; Matuszewska A; Wiland P
Arch Immunol Ther Exp (Warsz); 2015 Oct; 63(5):397-404. PubMed ID: 25837853
[TBL] [Abstract][Full Text] [Related]
37. Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib.
Anargyrou K; Terpos E; Vassilakopoulos TP; Pouli A; Sachanas S; Tzenou T; Masouridis S; Christoulas D; Angelopoulou MK; Dimitriadou EM; Kalpadakis C; Tsionos K; Panayiotidis P; Dimopoulos MA; Pangalis GA; Kyrtsonis MC;
Haematologica; 2008 Mar; 93(3):451-4. PubMed ID: 18287135
[TBL] [Abstract][Full Text] [Related]
38. Advances in the biology and treatment of myeloma bone disease.
Berenson JR
Semin Oncol; 2002 Dec; 29(6 Suppl 17):11-6. PubMed ID: 12520479
[TBL] [Abstract][Full Text] [Related]
39. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.
Berenson JR; Jagannath S; Barlogie B; Siegel DT; Alexanian R; Richardson PG; Irwin D; Alsina M; Rajkumar SV; Srkalovic G; Singhal S; Limentani S; Niesvizky R; Esseltine DL; Trehu E; Schenkein DP; Anderson K
Cancer; 2005 Nov; 104(10):2141-8. PubMed ID: 16206291
[TBL] [Abstract][Full Text] [Related]
40. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients.
Corso A; Mangiacavalli S; Varettoni M; Pascutto C; Zappasodi P; Lazzarino M
Leuk Res; 2010 Apr; 34(4):471-4. PubMed ID: 19674790
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]